Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Seals $330M RNAi IP Deal, $42.5M Investment with Roche

NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals said yesterday that it has closed its previously announced strategic alliance with Roche under which Roche agreed to license an Alnylam RNAi therapeutic technology platform and certain intellectual property, acquire one of Alnylam’s labs, and work with the firm on drug-discovery projects.
Under the agreement, Roche will make aggregate payments to Alnylam of around $331 million, including an upfront cash payment within ten business days of the closing in connection with the license.
In addition, the Roche Venture Fund has purchased 1.975 million shares of Alnylam common stock for a total of $42.5 million.
Roche also closed the purchase of an Alnylam lab in Kulmbach, Germany, for an undisclosed sum.
GenomeWeb Daily News sister publication RNAi News reported last month that Alnylam will have to pay around $30 million to other partners, primarily Isis Pharmaceuticals, from which it has licensed IP covered under the Roche deal.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.